Trading Report: Today, INNATE PHARMA EUR0.05 (IPHYF) Rating Decreased to Hold at The Zacks Investment Research

Today, INNATE PHARMA EUR0.05 (IPHYF) Rating Decreased to Hold at The Zacks Investment Research

INNATE PHARMA EUR0.05 (NASDAQ:IPHYF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.

According to Zacks, “Innate Pharma S.A. is a biopharmaceutical company. It develops drugs for treatment of cancer and inflammatory diseases. The company specializes in the development of first-in-class therapeutic antibodies targeting receptors and pathways controlling the activation of the innate immune system. Innate Pharma S.A. is headquartered in Marseilles, France. “

Separately, Leerink Swann restated a “buy” rating on shares of INNATE PHARMA EUR0.05 in a research note on Wednesday, August 17th.

INNATE PHARMA EUR0.05 (NASDAQ:IPHYF) traded up 2.11% during mid-day trading on Wednesday, reaching $15.00. 1,350 shares of the company were exchanged. The company’s 50 day moving average price is $12.86 and its 200-day moving average price is $12.54. The stock’s market capitalization is $808.16 million. INNATE PHARMA EUR0.05 has a 12-month low of $10.36 and a 12-month high of $16.00.

Related posts

Leave a Comment